Sign Up to like & get
recommendations!
1
Published in 2021 at "Disease Markers"
DOI: 10.1155/2021/4894022
Abstract: At present, the use of the common chemotherapy regimen CHOP/R-CHOP for diffuse large B-cell lymphoma (DLBCL) has some shortcomings, especially for relapsed and refractory DLBCL. CD47 is now considered as a prominent target in cancer…
read more here.
Keywords:
lymphoma dlbcl;
cd47;
large cell;
diffuse large ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Blood advances"
DOI: 10.1182/bloodadvances.2018023572
Abstract: Genomic rearrangements in the MYC locus occur in ∼12% of lymphomas with diffuse large B-cell lymphoma (DLBCL) morphology and are associated with inferior outcome. Previous studies exploring MYC rearrangements have primarily used fluorescence in situ…
read more here.
Keywords:
lymphoma dlbcl;
partner;
dlbcl morphology;
myc rearrangements ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s326632
Abstract: Abstract Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60–70% chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients are refractory or relapsing. Many attempts failed to improve the outcome…
read more here.
Keywords:
cell;
lymphoma;
lymphoma dlbcl;
cell lymphoma ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Current cancer drug targets"
DOI: 10.2174/1568009620666210106122750
Abstract: Diffuse large B cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin B cell lymphoma (NHL), and manifest highly heterogeneous genetic/phenotypic characteristics as well as variable responses to conventional immunochemotherapy (1). Genetic profiling…
read more here.
Keywords:
lymphoma dlbcl;
cell;
large cell;
diffuse large ... See more keywords